Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.137B
Cash
487.4M
Avg Qtr Burn
-21.04M
Short % of Float
10.34%
Insider Ownership
11.45%
Institutional Own.
80.76%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bitopertin (GlyT1 inhibitor) Details erythropoietic porphyrias, X-linked protoporphyria | NDA Submission | |
DISC-0974 Details Myelofibrosis, Anemia, Chronic kidney disease | Phase 2 Data readout | |
DISC-3405 (formerly MWTX-003) Details Polycythemia vera, Cancer, Blood cancer | Phase 2 Initiation | |
Bitopertin (GlyT1 inhibitor) Details Anemia, Rare genetic disease | Phase 1/2 Update | |
GEM103 Details Age-related macular degeneration | Failed Discontinued | |
GEM103 Details Wet age-related macular degeneration , Age-related macular degeneration | Failed Discontinued |